These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 18232649)

  • 1. Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin complex.
    Echalier A; Bettayeb K; Ferandin Y; Lozach O; Clément M; Valette A; Liger F; Marquet B; Morris JC; Endicott JA; Joseph B; Meijer L
    J Med Chem; 2008 Feb; 51(4):737-51. PubMed ID: 18232649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meriolins, a new class of cell death inducing kinase inhibitors with enhanced selectivity for cyclin-dependent kinases.
    Bettayeb K; Tirado OM; Marionneau-Lambot S; Ferandin Y; Lozach O; Morris JC; Mateo-Lozano S; Drueckes P; Schächtele C; Kubbutat MH; Liger F; Marquet B; Joseph B; Echalier A; Endicott JA; Notario V; Meijer L
    Cancer Res; 2007 Sep; 67(17):8325-34. PubMed ID: 17804748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of meriolins, a new class of cyclin-dependent kinase inhibitors, on malignant glioma proliferation and neo-angiogenesis.
    Jarry M; Lecointre C; Malleval C; Desrues L; Schouft MT; Lejoncour V; Liger F; Lyvinec G; Joseph B; Loaëc N; Meijer L; Honnorat J; Gandolfo P; Castel H
    Neuro Oncol; 2014 Nov; 16(11):1484-98. PubMed ID: 24891448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2-Anilino-4-(thiazol-5-yl)pyrimidine CDK inhibitors: synthesis, SAR analysis, X-ray crystallography, and biological activity.
    Wang S; Meades C; Wood G; Osnowski A; Anderson S; Yuill R; Thomas M; Mezna M; Jackson W; Midgley C; Griffiths G; Fleming I; Green S; McNae I; Wu SY; McInnes C; Zheleva D; Walkinshaw MD; Fischer PM
    J Med Chem; 2004 Mar; 47(7):1662-75. PubMed ID: 15027857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis, biological evaluation and molecular modeling of a novel series of 7-azaindole based tri-heterocyclic compounds as potent CDK2/Cyclin E inhibitors.
    Baltus CB; Jorda R; Marot C; Berka K; Bazgier V; Kryštof V; Prié G; Viaud-Massuard MC
    Eur J Med Chem; 2016 Jan; 108():701-719. PubMed ID: 26741853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variolins and related alkaloids.
    Walker SR; Carter EJ; Huff BC; Morris JC
    Chem Rev; 2009 Jul; 109(7):3080-98. PubMed ID: 19489543
    [No Abstract]   [Full Text] [Related]  

  • 7. Discovery of [4-Amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-yl](2,3-difluoro-6- methoxyphenyl)methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity.
    Chu XJ; DePinto W; Bartkovitz D; So SS; Vu BT; Packman K; Lukacs C; Ding Q; Jiang N; Wang K; Goelzer P; Yin X; Smith MA; Higgins BX; Chen Y; Xiang Q; Moliterni J; Kaplan G; Graves B; Lovey A; Fotouhi N
    J Med Chem; 2006 Nov; 49(22):6549-60. PubMed ID: 17064073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variolin B and its derivate deoxy-variolin B: new marine natural compounds with cyclin-dependent kinase inhibitor activity.
    Simone M; Erba E; Damia G; Vikhanskaya F; Di Francesco AM; Riccardi R; Bailly C; Cuevas C; Fernandez Sousa-Faro JM; D'Incalci M
    Eur J Cancer; 2005 Oct; 41(15):2366-77. PubMed ID: 16181779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and biological evaluation of N-alkyl or aryl substituted isoindigo derivatives as potential dual cyclin-dependent kinase 2 (CDK2)/glycogen synthase kinase 3β (GSK-3β) phosphorylation inhibitors.
    Zhao P; Li Y; Gao G; Wang S; Yan Y; Zhan X; Liu Z; Mao Z; Chen S; Wang L
    Eur J Med Chem; 2014 Oct; 86():165-74. PubMed ID: 25151579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel meriolin derivatives as rapid apoptosis inducers.
    Drießen D; Stuhldreier F; Frank A; Stark H; Wesselborg S; Stork B; Müller TJJ
    Bioorg Med Chem; 2019 Aug; 27(15):3463-3468. PubMed ID: 31248707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological study of novel pyrido[2,3-d]pyrimidine as anti-proliferative CDK2 inhibitors.
    Ibrahim DA; Ismail NS
    Eur J Med Chem; 2011 Dec; 46(12):5825-32. PubMed ID: 22000924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological evaluation of 1-aryl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of cyclin-dependent kinases.
    Markwalder JA; Arnone MR; Benfield PA; Boisclair M; Burton CR; Chang CH; Cox SS; Czerniak PM; Dean CL; Doleniak D; Grafstrom R; Harrison BA; Kaltenbach RF; Nugiel DA; Rossi KA; Sherk SR; Sisk LM; Stouten P; Trainor GL; Worland P; Seitz SP
    J Med Chem; 2004 Nov; 47(24):5894-911. PubMed ID: 15537345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administration.
    Heathcote DA; Patel H; Kroll SH; Hazel P; Periyasamy M; Alikian M; Kanneganti SK; Jogalekar AS; Scheiper B; Barbazanges M; Blum A; Brackow J; Siwicka A; Pace RD; Fuchter MJ; Snyder JP; Liotta DC; Freemont PS; Aboagye EO; Coombes RC; Barrett AG; Ali S
    J Med Chem; 2010 Dec; 53(24):8508-22. PubMed ID: 21080703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concise syntheses of meridianins and meriolins using a catalytic domino amino-palladation reaction.
    Walker SR; Czyz ML; Morris JC
    Org Lett; 2014 Feb; 16(3):708-11. PubMed ID: 24437527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substituted 4-(thiazol-5-yl)-2-(phenylamino)pyrimidines are highly active CDK9 inhibitors: synthesis, X-ray crystal structures, structure-activity relationship, and anticancer activities.
    Shao H; Shi S; Huang S; Hole AJ; Abbas AY; Baumli S; Liu X; Lam F; Foley DW; Fischer PM; Noble M; Endicott JA; Pepper C; Wang S
    J Med Chem; 2013 Feb; 56(3):640-59. PubMed ID: 23301767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and biological evaluation of novel pyrimidine derivatives as CDK2 inhibitors.
    Ibrahim DA; El-Metwally AM
    Eur J Med Chem; 2010 Mar; 45(3):1158-66. PubMed ID: 20045222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indazolylpyrazolopyrimidine as highly potent B-Raf inhibitors with in vivo activity.
    Wang X; Berger DM; Salaski EJ; Torres N; Dutia M; Hanna C; Hu Y; Levin JI; Powell D; Wojciechowicz D; Collins K; Frommer E; Lucas J
    J Med Chem; 2010 Nov; 53(21):7874-8. PubMed ID: 20961062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, and biological evaluation of dinaciclib and CAN508 hybrids as CDK inhibitors.
    Odeh DM; Allam HA; Baselious F; Mahmoud WR; Odeh MM; Ibrahim HS; Abdel-Aziz HA; Mohammed ER
    Drug Dev Res; 2024 May; 85(3):e22193. PubMed ID: 38685605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model.
    Singh U; Chashoo G; Khan SU; Mahajan P; Nargotra A; Mahajan G; Singh A; Sharma A; Mintoo MJ; Guru SK; Aruri H; Thatikonda T; Sahu P; Chibber P; Kumar V; Mir SA; Bharate SS; Madishetti S; Nandi U; Singh G; Mondhe DM; Bhushan S; Malik F; Mignani S; Vishwakarma RA; Singh PP
    J Med Chem; 2017 Dec; 60(23):9470-9489. PubMed ID: 29144137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of novel indirubin-3'-monoxime derivatives as potent inhibitors against CDK2 and CDK9.
    Yan L; Lai F; Chen X; Xiao Z
    Bioorg Med Chem Lett; 2015 Jun; 25(11):2447-51. PubMed ID: 25908517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.